Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Kymera Therapeutics, Inc.
< Previous
1
2
Next >
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
November 02, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
November 01, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
October 27, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
October 26, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
October 16, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
September 18, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
August 28, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
August 03, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
July 27, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
June 22, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
June 14, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
June 09, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
June 09, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Participate in Upcoming June Investor Conference
June 01, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
May 22, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
May 19, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
May 18, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
May 04, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
April 11, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
March 01, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
February 23, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
February 01, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
January 10, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
January 04, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
January 03, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
December 14, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
December 12, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
December 11, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
December 01, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
November 03, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.